Humanigen — Investor Presentation (June 2018)
20 slides from Humanigen's investor presentation, Jun 5, 2018
Slide 1: Enhancing T-Cell Therapies in Oncology
Enhancing T-Cell Therapies in Oncology OTCQB: HGENwww.humanigen.com 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding fu
Slide 3: Strategic Focus – Enhancing T-Cell Therapies in Oncology
Strategic Focus – Enhancing T-Cell Therapies in Oncology Short, Medium and Long-Term Growth Drivers: 3 Focus on CAR-T- induced AEs to prevent onset/severity of neurotoxicitySevere patient risk factor, also impacting clinical trial holds, commercial uptake and hospital resources Focus on optimizing C
Slide 4: Big Commercial, Partnering Universe in T-Cell Therapy
Big Commercial, Partnering Universe in T-Cell Therapy 4
Slide 5: Experienced, Execution-Focused Leadership and Board; Extensive CAR-T and Immuno-Oncology Expertise
Experienced, Execution-Focused Leadership and Board; Extensive CAR-T and Immuno-Oncology Expertise Cameron Durrant, MD, MBACEOPharma and serial biotech execPharmacia/Pfizer, J+J in the US; Merck, GSK in EuropeBiotech Exec Chairman, Chairman, CEO, CFO Greg Jester, CPA CFO Decades of financial, operat
Slide 6: 'Achilles Heel' of CAR-T: Neurotoxicity, Cytokine Release Syndrome
‘Achilles Heel’ of CAR-T: Neurotoxicity (NT), Cytokine Release Syndrome (CRS) Up to 87% with NT and 94% with CRS*One-third/one-half of patients have grade ≥3 NT, potential ICU admissionSeveral deaths *Package insert for KYMRIAH, YESCARTA www.cellculturedish.com 6
Slide 7: Myeloid and CAR-T Cells' Increase in Brain Associated with NT
Myeloid and CAR-T Cells’ Increase in Brain Associated with NT 7 Cell Populations (in CSF) NE Grade 0-2 (n=15)Median cells/mL(Q1, Q3) NE Grade > 3 (N=10)Median cells/mL(Q1, Q3) NE Grade > 3/Grade 0-2Ratio CD45+ (leukocytes) 166 (18, 1504) 570 (170, 1700) 3.4 CD14+ (myeloid cells) 18 (11, 436) 306 (12
Slide 8: GM-CSF from T Cells Triggers Central Nervous System Damage
Zhao, et al. GM-CSF-Commanding CNS Invasion. Immunity 46. Feb 21, 2017 GM-CSF production by T cells starts expansion of monocyte-derived cells (MdC) and CNS inflammationMdCs produce IL-1 and ROS, cross BBB and activate microgliaMicroglia secrete CCL2, recruit CCR2-expressing inflammatory MdCs into t
Slide 9: Fever and Elevated MCP-1 (CCL2) Predict Severe CRS, NT
Patients with fever and very high MCP-1 generally develop severe CRS and NT within 36 hours of infusionMCP-1 regulated by GM-CSF Gust, Turtle, et al. Cancer Discovery. Oct 2017, DOI: 10.1158/2159-8290.CD-17-0698 9 Fever and Elevated MCP-1 (CCL2) Predict Severe CRS, NT B-ALL CLL NHL
Slide 10: Evidence Shows Strong GM-CSF Link to Neurotoxicity
Evidence Shows Strong GM-CSF Link to Neurotoxicity Elevated GM-CSF associated with grade > 3 NTIL-2 only other cytokine with this association Published clinical association in Zuma-1 trial Locke, Neelapu et al, AACR 2017 10
Slide 11: Scientific Rationale Points to GM-CSF Trigger to CAR-T A/Es
Sentman, et al. www.jimmunol.org/content/197/12/4674.long; Coxford, et al. Immunity 2015 (43)510-514; Ishii, et al. Blood 2016 128:3358; Teachey, et al. Cancer Discov. 2016 June ; 6(6): 664–679. doi:10.1158/2159-8290.CD-16-0040; Lee, et al. Blood 2016 124:2:188; David M. Barrett et al. Blood 2016;12
Slide 12: Lenzilumab: First-in-Class, Anti-GM-CSF Monoclonal Antibody
Lenzilumab: First-in-Class, Anti-GM-CSF Monoclonal Antibody Lenzilumab Binds to and neutralizes circulating GM-CSF Safety and tolerability well established from one Phase I, two Phase II studies Compelling safety and tolerability profile in over 100 patientsEfficacy signals in Phase II eosinophilic
Slide 13: In Vivo Preclinical Data: Positive Survival, Proliferation
More robust proliferation after treatment with lenzilumab in vivo (~5x) Lenzilumab does not impede CAR-T cell function in vivo in the absence of PBMCsSurvival similar for CAR-T + control and CAR-T + lenzilumab In Vivo Preclinical Data: Positive Survival, Proliferation 13 Kenderian, S: Presentation a
Slide 14: Lenzilumab CAR-T Development Plan Has Top KOL Support
Lenzilumab CAR-T Development Plan Has Top KOL Support 14 Top KOLs understand GM-CSF as target KOLs proactively offered to study neurotoxicity prevention Lenzilumab pivotal study as prophylactic therapy prior to CAR-T infusion to prevent NT with YESCARTA, expected start 2H 2018 at MD Anderson (with l
Slide 15: HGEN Scientific Advisory Board Input From Top KOLs at Leading Centers
HGEN Scientific Advisory Board Input From Top KOLs at Leading Centers 15 Massachusetts General Hospital, HarvardMoffittOlivia Newton-John Cancer Research InstituteMemorial Sloan Kettering Cancer CenterCHOPU PennDana Farber Cancer Institute HarvardMayo ClinicSeattle Children’sUniversity of FloridaMD
Slide 16: Framing Lenzilumab's Extensive Value Potential
Framing Lenzilumab’s Extensive Value Potential GM-CSF neutralization reduces MDSC IDO and PD-L1 expression Lenzilumab as ‘booster’ of CAR-T: in vivo cell expansion data One-third to a half of patients require ICU stay Prophylactic lenzilumab to prevent onset of CAR-T potentially life-threatening sid
Slide 17: Ifabotuzumab: First-in-Class, EphA3 Monoclonal Antibody
Ifabotuzumab: First-in-Class, EphA3 Monoclonal Antibody Targets Eph receptor A3 Phase I bio-imaging study in glioblastoma multiforme (GBM), promising initial resultsCAR being designed Developed an Antibody Drug Conjugate EphA3 Receptor Ifabotuzumab INTRACELLULAR Inhibition of cell positioning, survi
Slide 18: Monoclonal Antibody Pipeline
Monoclonal Antibody Pipeline Preclinical Phase I Phase II Phase III BLA Lenzilumab(anti-GM-CSF mAb) Prophylaxis CAR-T-induced serious A/Es, potential improved efficacy (CAR-T companion/booster) CMML (monotherapy in salvage patients - fully enrolled) Ifabotuzumab(anti-EphA3 mAb) GBM (monotherapy in s
Slide 19: Vigorous Partnering Activity in this Field
Vigorous Partnering Activity in this Field 19
Slide 20: Summary
Summary Top KOLs back scientific rationale for lenzilumab starting pivotal trials Lenzilumab has potential to make CAR-T safer, more effective and a more routine out-patient procedure Not enough ICU beds for numbers of patients necessary to hit analyst forecasts; hospital reimbursement additional ga